Third Rock eyes a Cambridge, MA, beachhead as biotech gets priced out

As growing demand for lab space in Cambridge, MA, threatens to price out startups, biotech foundry Third Rock Ventures is looking to make a splash in the neighborhood to give its seedlings access to one of the industry's most vibrant innovation hubs, Beta Boston reports. The company is considering "new master space agreement that can fit multiple companies over time," partner Alexis Borisy told Beta Boston, but has yet to cement a deal. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.